Aventis Pharm and Qiagen Sign Deal for Non-PCR Microarray Platform | GenomeWeb

NEW YORK, June 28 - Qiagen and Aventis have signed a technology access agreement for Qiagen's new ZeptoGene Workstation microarray platform, Qiagen said Thursday. 

Under the agreement, Aventis will acquire limited access to the platform, which can be used for both nucleic acid and protein analysis.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."